These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 20068101)

  • 1. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
    Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
    Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.
    Rosen PJ; Sweeney CJ; Park DJ; Beaupre DM; Deng H; Leitch IM; Shubhakar P; Zhu M; Oliner KS; Anderson A; Yee LK
    Clin Cancer Res; 2010 May; 16(9):2677-87. PubMed ID: 20406832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
    Tolcher AW; Sarantopoulos J; Patnaik A; Papadopoulos K; Lin CC; Rodon J; Murphy B; Roth B; McCaffery I; Gorski KS; Kaiser B; Zhu M; Deng H; Friberg G; Puzanov I
    J Clin Oncol; 2009 Dec; 27(34):5800-7. PubMed ID: 19786654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
    Rosen LS; Kurzrock R; Mulay M; Van Vugt A; Purdom M; Ng C; Silverman J; Koutsoukos A; Sun YN; Bass MB; Xu RY; Polverino A; Wiezorek JS; Chang DD; Benjamin R; Herbst RS
    J Clin Oncol; 2007 Jun; 25(17):2369-76. PubMed ID: 17557949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
    Herbst RS; Hong D; Chap L; Kurzrock R; Jackson E; Silverman JM; Rasmussen E; Sun YN; Zhong D; Hwang YC; Evelhoch JL; Oliner JD; Le N; Rosen LS
    J Clin Oncol; 2009 Jul; 27(21):3557-65. PubMed ID: 19546406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.
    Hotte SJ; Hirte HW; Chen EX; Siu LL; Le LH; Corey A; Iacobucci A; MacLean M; Lo L; Fox NL; Oza AM
    Clin Cancer Res; 2008 Jun; 14(11):3450-5. PubMed ID: 18519776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.
    Schöffski P; Garcia JA; Stadler WM; Gil T; Jonasch E; Tagawa ST; Smitt M; Yang X; Oliner KS; Anderson A; Zhu M; Kabbinavar F
    BJU Int; 2011 Sep; 108(5):679-86. PubMed ID: 21156020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.
    Clark JW; Eder JP; Ryan D; Lathia C; Lenz HJ
    Clin Cancer Res; 2005 Aug; 11(15):5472-80. PubMed ID: 16061863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of pazopanib in patients with advanced cancer.
    Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
    Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
    Herbst RS; Eckhardt SG; Kurzrock R; Ebbinghaus S; O'Dwyer PJ; Gordon MS; Novotny W; Goldwasser MA; Tohnya TM; Lum BL; Ashkenazi A; Jubb AM; Mendelson DS
    J Clin Oncol; 2010 Jun; 28(17):2839-46. PubMed ID: 20458040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
    Advani RH; Hurwitz HI; Gordon MS; Ebbinghaus SW; Mendelson DS; Wakelee HA; Hoch U; Silverman JA; Havrilla NA; Berman CJ; Fox JA; Allen RS; Adelman DC
    Clin Cancer Res; 2010 Apr; 16(7):2167-75. PubMed ID: 20233886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
    Papadopoulos KP; Goel S; Beeram M; Wong A; Desai K; Haigentz M; Milián ML; Mani S; Tolcher A; Lalani AS; Sarantopoulos J
    Clin Cancer Res; 2008 Nov; 14(21):7110-5. PubMed ID: 18981010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
    Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
    J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
    Advani R; Forero-Torres A; Furman RR; Rosenblatt JD; Younes A; Ren H; Harrop K; Whiting N; Drachman JG
    J Clin Oncol; 2009 Sep; 27(26):4371-7. PubMed ID: 19636010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.
    Rosen LS; Senzer N; Mekhail T; Ganapathi R; Chai F; Savage RE; Waghorne C; Abbadessa G; Schwartz B; Dreicer R
    Clin Cancer Res; 2011 Dec; 17(24):7754-64. PubMed ID: 21976535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
    Doi T; Murakami H; Ohtsu A; Fuse N; Yoshino T; Yamamoto N; Boku N; Onozawa Y; Hsu CP; Gorski KS; Friberg G; Kawaguchi T; Sasaki T
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):733-41. PubMed ID: 21161528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.
    Paz-Ares LG; Gomez-Roca C; Delord JP; Cervantes A; Markman B; Corral J; Soria JC; Bergé Y; Roda D; Russell-Yarde F; Hollingsworth S; Baselga J; Umana P; Manenti L; Tabernero J
    J Clin Oncol; 2011 Oct; 29(28):3783-90. PubMed ID: 21900113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.